论文部分内容阅读
在美国,接受血液透析(血透)患者的每年死亡率1982年为20.0%,1988年增加到23.4%。一些研究认为,长期血透患者死亡率的增加与血清铝浓度增高有关。本研究评价了长期血透患者死亡率与血清铝浓度间的关系。病人和方法 1986年1月和1988年6月进行血清铝浓度测定的血透患者10646例为研究对象,其中部分患者自1980年1月就开始接受血透治疗。血透患者的生存时间从第1次测定血清铝浓度时起计算。如果病人作过1次以上的血清铝浓度测定,仅以第1次测定的浓度作为分析浓度。同时收集患者人口学和临床有关资料。结果 90%以上患者血清铝浓度高于正常值上限
In the United States, the annual mortality rate for hemodialysis patients is 20.0% in 1982 and 23.4% in 1988. Some studies suggest that increased long-term hemodialysis mortality is associated with elevated serum aluminum concentrations. This study evaluated the relationship between long-term hemodialysis mortality and serum aluminum concentrations. Patients and Methods A total of 10,646 hemodialysis patients whose serum aluminum levels were measured in January 1986 and June 1988 were included in the study. Some of them received hemodialysis as of January 1980. The survival time of hemodialysis patients was calculated from the time when the serum aluminum concentration was measured for the first time. If the patient has done more than one serum aluminum concentration determination, only the first determination of the concentration as the analysis of concentration. At the same time collect patient demography and clinical information. Results Serum aluminum concentrations in more than 90% of patients were higher than the upper limit of normal